Trial · NCT03653338

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

NCT03653338, Phase 1, Phase 2, Recruiting, Paul Szabolcs

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias. Trials, record NCT03653338. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03653338

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
NCT number: NCT03653338
Status: Recruiting
Phases: Phase 1, Phase 2
Enrollment: 5 participants, estimated
Lead sponsor: Paul Szabolcs
Conditions: Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa
First posted: 2018-08-31
Last updated: 2026-08-13

Source ClinicalTrials.gov

Registered outcomes20

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Graft rejection	Day -30 through study completion, an average of 2 years	How frequent, if any, graft rejection occurs
Primary	Post Transplant treatment related mortality	By day 100	Number of deaths that occurred from treatment
Primary	Acute Graft versus host disease	Day 0 through study completion, an average of 2 years	The number of patients who develop acute graft versus host disease (GVHD)post transplant
Primary	Chronic Graft versus host disease	Day 0 through study completion, an average of 2 years	The number of patients who develop chronic graft versus host disease (GVHD) post transplant
Primary	Post Transplant treatment related mortality	Day 180	Number of deaths that occurred from treatment
Primary	Post Transplant treatment related mortality	1 year	Number of deaths that occurred from treatment
Secondary	Neutrophil recovery	Day 0 through study completion, an average of 2 years	≥ 0.5 x 103/μL neutrophils for three consecutive days tested on different days.
Secondary	Donor Cell Engraftment	From Day 0, Day 42, Day 100 and Day 180. Further testing can be done if clinically indicated up to 2 years post transplant	≥ 5% donor cells on day +42 and ≥ 10% donor cells on day +100. We will record if subjects have attained robust donor cell engraftment (\> 50% donor chimerism at 180 days).
Secondary	Neurological complications	Day 0 through study completion, an average of 2 years	To evaluate the incidence of neurological complications
Secondary	Immune reconstitution	Day 0 through study completion, an average of 2 years	The pace of systemic immune reconstitution

1 to 10 of 20Source ClinicalTrials.gov

See all 20 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03653338

GET https://conductscience.org/api/trials/v1/NCT03653338/registered

API reference For AI assistants